Oragenics Inc (NYSEAMERICAN: OGEN) is having an overwhelmingly strong start to the trading session this morning. A dive into press releases shows that there’s no new news that has been released. However, there’s a good reason for the gains. Investors are ultimately excited about a data presentation that will be taking place in just a few hours. Today, we’ll talk about:
- The data presentation;
- what we’re seeing from OGEN; and
- what we’ll be watching for with regard to the stock ahead.
OGEN To Present Data Today
As mentioned above, Oragenics is flying in the market this morning as investors await a coming presentation. On September 17th, the company announced that it would be presenting clinical data relatively soon. Well, the time has come. At 12:55 PM MT, the company will be presenting data on its lantibiotics program. The program is being developed for the treatment of serious and prevalent infectious diseases. The presentation will take place at the Boulder Peptide Symposium in just a few hours.
During the presntation, Dr. Martin Handfield, SVP of Discovery Rearch at OGEN, will be discussing Mutacin 1140 (MU1140). MU1140 is a lanthipeptide isolated from Streptococus mutans that has shown activity against all Gram-positive bacteria that it has been tested against. The company said that a variant of MU1140 was engineered and triaged from a library of over 700 single and multiple variants of MU1140. From there, the company identified OG716 as the lead compound against Clostridium difficile associated diseasee.
In the release announcing the presentation, OGEN said that in pre-clinical studies, OG716 showed an in vitro potency equal or superior to “standard of care” drugs against drug-resistant bacteria. Moreover, the data suggests that OG716 ihas superior safety, toxicity and stability profiles.
With the full data presentation coming today, investors are expecting the best, which can be seen through the impressive movement we’re watching in the OGEN chart.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to invest is that the news moves the market. When it comes to Oragenics, the news is old, but the presentation is yet to take place, so the catalyst is just around the corner. Investors are excited about a presentation that will take place in just a few hours, pushing the stock for the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:51), OGEN is trading at $0.89 per share after a gain of $0.17 per share or 23.60% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on OGEN. In particular, we’re interested in following the story surrounding the company’s continued work with regard to OG716 and its potential to treat drug-resistant bacteria strains. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!